Stocks● Neutral
FDA Clears Stereotaxis Synchrony System for Robotic Surgery
Cloud-based connectivity in the new Synchrony platform aims to streamline cardiac arrhythmia treatment. The launch marks a shift toward digital scaling.
Continue with
Stereotaxis (NYSE: STXS) announced on Tuesday that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Synchrony system. Following the regulatory approval, the company has officially launched the platform to the medical market.
The Synchrony system represents a significant modernization of the company’s catheterization laboratory technology. A primary feature of the new platform is the integration of cloud-based connectivity, which is designed to enhance data management and operational efficiency within clinical environments. The company expects the rollout of this technology to improve the capabilities of robotic-assisted surgical procedures.
Stereotaxis specializes in innovative robotic technologies for the treatment of cardiac arrhythmias. By incorporating cloud connectivity into the Synchrony platform, the company aims to streamline the workflow for healthcare providers utilizing its robotic systems. The launch marks a transition for Stereotaxis as it seeks to scale its digital infrastructure alongside its established surgical hardware.